satralizumab   Click here for help

GtoPdb Ligand ID: 9093

Synonyms: Enspryng® | RG-6168 | RG6168 | SA-237 | SA237 | sapelizumab (deprecated INN) | satralizumab-mwge
Approved drug Immunopharmacology Ligand
satralizumab is an approved drug (Canada, Japan and FDA (2020), EMA (2021))
Compound class: Antibody
Comment: Satralizumab (previously referred to using the replaced INN sapelizumab) is an investigational humanized monoclonal antibody targeting the IL-6 receptor, with immunomodulatory potential. This antibody is an improved version of tocilizumab, with enhanced antigen-neutralizing ability and pharmacokinetics suitable for less frequent administration [2].
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. Peptide BLAST searches reveal identical matches between the heavy and light chain sequences as annotated in IMGT and SEQ IDs 26 and 29 respectively claimed in patent US8562991 [2]. This matches satralizumab to the Fv4-M73 construct in the patent.
Click here for help
Classification Click here for help
Compound class Antibody
Approved drug? Yes (Canada, Japan and FDA (2020), EMA (2021))
International Nonproprietary Names Click here for help
INN number INN
10065 satralizumab
Synonyms Click here for help
Enspryng® | RG-6168 | RG6168 | SA-237 | SA237 | sapelizumab (deprecated INN) | satralizumab-mwge
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 586
Other databases
GtoPdb PubChem SID 315661178
Search PubMed clinical trials satralizumab
Search PubMed titles satralizumab
Search PubMed titles/abstracts satralizumab